Base Year
Historical Year
Forecast Year
The value of the global schizophrenia drugs market was USD 8.18 billion in 2023, driven by the prevalence of schizophrenia across the globe. The market is expected to grow at a CAGR of 3.9% during the forecast period of 2024-2032 to reach value of USD 11.56 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Schizophrenia is a chronic brain disorder that affects a person’s ability to think, feel, and act. The patient can experience symptoms such as hallucinations, delusions, and show extremely disordered thinking and behaviour that may hinder their daily activities.
With the growing geriatric population, the number of cases of mental disorders is increasing as old people are more prone to such diseases.
Long acting injectables are growing in adoption due to concerns related to non-adherence to oral schizophrenia medication and the potential for relapses and psychotic symptoms. LAIs have a lower rate of non-adherence as they have fewer adverse effects compared to oral medications.
Manufacturers have increased their research and development activities with the rise in the number of clinical trials in support of the development of novel treatments for schizophrenia.
Healthcare companies are innovating medication manufacturing by utilising high-content single-cell screenings. The development of new potential drugs would be done on a live cellular function model, which will help manufacturers to develop drugs in less time and at effective pricing.
Majority of the currently available oral drugs for schizophrenia have limited efficacy and can result in negative symptoms with a possibility of relapse in case of non-adherence. Some case may even show severe consequences.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on therapeutic class, the market can be segmented into second-generation antipsychotics and third-generation antipsychotics, among others. Based on treatments, it can be bifurcated into oral and injectables. Based on distribution channels, they can be divided into hospital pharmacies, retail pharmacies, and online, among others. The regional markets for the schizophrenia drugs market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global schizophrenia drugs market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
Based on treatment, the market for schizophrenia drugs can be bifurcated into oral and injectables. With the development of new key products for the treatment of schizophrenia as a result of the growing number of people suffering from the disease, the injectable segment is expected to hold a major share of the market.
Additionally, several key players in the market have started making substantial investments in research and development for novel treatment solutions.
Injectable-based schizophrenia medications, particularly long-acting injectables, are increasingly gaining popularity owing to their benefits and fewer adverse effects. They also help in suppressing the drawbacks associated with oral treatments. This development in schizophrenia drugs can help the market to grow further with improved patient outcomes and fewer relapses.
Based on distribution channels, the market bifurcations include hospital pharmacies, retail pharmacies, and online, among others.
The hospital pharmacy segment is expected to dominate the market, owing to the existence of trained psychiatrists who continue to operate in large hospitals and an increasing number of people with schizophrenia, as well as the increase of long-acting injectables, which physicians may utilise in their normal practice.
Following the hospital pharmacy, the online segment is expected to register the highest CAGR owing to the rapid expansion of internet services and smart devices around the world. People are also shifting towards online services due to the convenience of filling up prescriptions from home.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Eli Lilly and Company is a pharmaceutical company based in the United States, with their headquarters in Indiana. They distribute their products in approximately 125 countries. The company has been in service since 1876. The company works on multiple diseases including Alzheimer’s, Cancer, Diabetes, Immunology, Obesity, and Pain.
AbbVie Inc. is an American pharmaceutical research and development company, which was founded in 2013. They provide therapeutic services for various areas of disease such as neuroscience, virology, oncology, immunology, and eye care. The company is increasingly invested to develop and deliver new medications.
Alkermes PLC is one of the key global biopharmaceutical companies, which was founded in 1987 and is headquartered in Ireland. The company is engaged in the development of innovative medicines in the medical field of neuroscience and oncology.
Other Key players include Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Schizophrenia Drugs Market Size
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is expected to grow at a CAGR of 3.9% during the period 2024-2032.
The market is driven by the increasing number of cases of schizophrenia and the wide adoption of long-acting injectables due to their benefits of reduced relapse of the patient.
The rising investment and industrial collaborations in the development of novel treatments for schizophrenia are key trends followed in the market.
The regional markets for the global schizophrenia drugs market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The different therapeutic classes in the market include second-generation antipsychotics and third-generation antipsychotics, among others.
The different types of treatment in the market include oral and injectables.
The distribution channels used for schizophrenia drugs include hospital pharmacies, retail pharmacies, and online, among others.
The key players in the market include Eli Lilly and Company, AbbVie Inc., Alkermes PLC, Otsuka Pharmaceutical Co., Ltd., and Johnson & Johnson Services, Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share